Next Article in Journal
Effects of Quercetin in a Rat Model of Hemorrhagic Traumatic Shock and Reperfusion
Next Article in Special Issue
The Potential of Cyclodextrins as Novel Active Pharmaceutical Ingredients: A Short Overview
Previous Article in Journal
Natural Products in Anti-Obesity Therapy
Previous Article in Special Issue
Alpha- and Beta-Cyclodextrin Inclusion Complexes with 5-Fluorouracil: Characterization and Cytotoxic Activity Evaluation
Open AccessReview

Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases

1
Laboratoire de la barrière hémato-encéphalique (LBHE), University Artois, EA 2465, Lens, F-62300, France
2
Unité de Catalyse et de Chimie du Solide (UCCS), University Artois, CNRS, UMR 8181, Lens, F-62300, France
3
ROQUETTE, Nutrition & Health R & D, 62136 Lestrem, France
*
Authors to whom correspondence should be addressed.
Academic Editor: Bernard Martel
Molecules 2016, 21(12), 1748; https://doi.org/10.3390/molecules21121748
Received: 9 November 2016 / Revised: 13 December 2016 / Accepted: 14 December 2016 / Published: 20 December 2016
(This article belongs to the Special Issue Cyclodextrin Chemistry)
Cardiovascular diseases, like atherosclerosis, and neurodegenerative diseases affecting the central nervous system (CNS) are closely linked to alterations of cholesterol metabolism. Therefore, innovative pharmacological approaches aiming at counteracting cholesterol imbalance display promising therapeutic potential. However, these approaches need to take into account the existence of biological barriers such as intestinal and blood-brain barriers which participate in the organ homeostasis and are major defense systems against xenobiotics. Interest in cyclodextrins (CDs) as medicinal agents has increased continuously based on their ability to actively extract lipids from cell membranes and to provide suitable carrier system for drug delivery. Many novel CD derivatives are constantly generated with the objective to improve CD bioavailability, biocompatibility and therapeutic outcomes. Newly designed drug formulation complexes incorporating CDs as drug carriers have demonstrated better efficiency in treating cardiovascular and neurodegenerative diseases. CD-based therapies as cholesterol-sequestrating agent have recently demonstrated promising advances with KLEPTOSE® CRYSMEB in atherosclerosis as well as with the 2-hydroxypropyl-β-cyclodextrin (HPβCD) in clinical trials for Niemann-Pick type C disease. Based on this success, many investigations evaluating the therapeutical beneficial of CDs in Alzheimer’s, Parkinson’s and Huntington’s diseases are currently on-going. View Full-Text
Keywords: cyclodextrins; cholesterol; atherosclerosis; neurodegenerative diseases; vascular diseases; Niemann-Pick disease type C (NPC); Alzheimer’s disease (AD); blood-brain barrier (BBB); HPβCD; KLEPTOSE® CRYSMEB cyclodextrins; cholesterol; atherosclerosis; neurodegenerative diseases; vascular diseases; Niemann-Pick disease type C (NPC); Alzheimer’s disease (AD); blood-brain barrier (BBB); HPβCD; KLEPTOSE® CRYSMEB
Show Figures

Figure 1

MDPI and ACS Style

Coisne, C.; Tilloy, S.; Monflier, E.; Wils, D.; Fenart, L.; Gosselet, F. Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases. Molecules 2016, 21, 1748.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop